Different in situ immune patterns of S-CD3+ and S-CD8+ as well as PD-L1 expression status of stromal T cells may result in different immune-related pathologic response between PTs and mLNs in NSCLC patients. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.